Asian Pacific Journal of Cancer Prevention

  • 제17권8호
  • /
  • Pages.3697-3703
  • /
  • 2016
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Advances in Management of Hepatocellular Carcinoma

  • Intaraprasong, Pongphob (Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University) ;
  • Siramolpiwat, Sith (Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University) ;
  • Vilaichone, Ratha-korn (Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University)
  • 발행 : 2016.08.01
⟨ 이전 논문 다음 논문 ⟩

초록

Hepatocellular carcinoma (HCC) is the most frequent type of malignant liver tumor and a high impact health problem worldwide. The prevalence of HCC is particularly high in many Asian and African countries. Some HCC patients have no symptoms prior to diagnosis and many of them therefore present at late stage and have a grave prognosis. The well-established causes of HCC are chronic hepatitis B virus (HBV) or chronic hepatitis C virus (HCV) infection or alcoholic cirrhosis and nonalcoholic steatohepatitis. The Barcelona Clinic Liver Cancer (BCLC) Staging System remains the most widely used for HCC management guidelines. To date, the treatments for HCC are still very challenging for physicians due to limited resources in many parts of the world, but many options of management have been proposed, including hepatic resection, liver transplantation, ablative therapy, chemoembolization, sorafnib and best supportive care. This review article describes the current evidence-based management of HCC with focus on early to advance stages that impact on patient overall survival.

키워드

참고문헌

  1. Abou-Alfa GK, Schwartz L, Ricci S, et al (2006). Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol, 24, 4293-0. https://doi.org/10.1200/JCO.2005.01.3441
  2. Bhangui P, Vibert E, Majno P, et al (2011). Intention-totreat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation. Hepatolo, 53, 1570-79. https://doi.org/10.1002/hep.24231
  3. Bhoori S, Mazzaferro V (2014). Current challenges in liver transplantation for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol, 28, 867-79. https://doi.org/10.1016/j.bpg.2014.08.001
  4. Berzigotti A, Reig M, Abraldes JG, et al (2015). Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatol, 61, 526-36. https://doi.org/10.1002/hep.27431
  5. Bruix J, Castells A, Bosch J, et al (1996). Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterol, 111, 1018-22. https://doi.org/10.1016/S0016-5085(96)70070-7
  6. Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatol, 53, 1020-2. https://doi.org/10.1002/hep.24199
  7. Bruix J, Sherman M, American Association for the Study of Liver D (2011). Management of hepatocellular carcinoma: an update. Hepatol, 53, 1020-2. https://doi.org/10.1002/hep.24199
  8. Bruix J, Takayama T, Mazzaferro V, et al (2015). Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol, 16, 1344-54. https://doi.org/10.1016/S1470-2045(15)00198-9
  9. Chapman WC, Majella Doyle MB, Stuart JE, et al (2008). Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg, 248, 617-25.
  10. Cheng AL, Kang YK, Chen Z, et al (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo- controlled trial. Lancet Oncol, 10, 25-34. https://doi.org/10.1016/S1470-2045(08)70285-7
  11. Cho YK, Kim JK, Kim MY, et al (2009). Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatol, 49, 453-9. https://doi.org/10.1002/hep.22648
  12. Clavien PA, Lesurtel M, Bossuyt PM, et al (2012). Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol, 13, 11-22. https://doi.org/10.1016/S1470-2045(11)70175-9
  13. Couto OF, Dvorchik I, Carr BI (2007). Causes of death in patients with unresectable hepatocellular carcinoma. Dig Diseases Sci, 52, 3285-9. https://doi.org/10.1007/s10620-007-9750-3
  14. Crissien AM, Frenette C (2014). Current management of hepatocellular carcinoma. Gastroenterol Hepatol (NY), 10, 153-61.
  15. Cucchetti A, Ercolani G, Vivarelli M, et al (2009). Is portal hypertension a contraindication to hepatic resection? Ann Surg, 250, 922-8. https://doi.org/10.1097/SLA.0b013e3181b977a5
  16. De Luna W, Sze DY, Ahmed A, et al (2009). Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transplant, 9, 1158-68. https://doi.org/10.1111/j.1600-6143.2009.02576.x
  17. Dong B, Liang P, Yu X, et al (2003). Percutaneous sonographically guided microwave coagulation therapy for hepatocellular carcinoma: results in 234 patients. AJR Am J Roentgenol, 180, 1547-55. https://doi.org/10.2214/ajr.180.6.1801547
  18. Earl TM, Chapman WC (2013). Transplantation for hepatocellular carcinoma: the North American
  19. Chunlertrith K, Sukeepaisarnjaroen W, Mairiang P , et al (2000). Clinico-epidemiology of hepatitis C viral infection in northeastern Thailand. Southeast Asian J Trop Med Public Health, 31, 273-6.
  20. Southeast Asian J Trop Med Public Health experience. Recent Results Cancer Res, 190, 145-64.
  21. El-Serag HB (2011). Hepatocellular carcinoma. N Engl J Med, 365, 1118-27. https://doi.org/10.1056/NEJMra1001683
  22. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer (2012). EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatolol, 56, 908-43. https://doi.org/10.1016/j.jhep.2011.12.001
  23. Farges O, Belghiti J, Kianmanesh R, et al (2003). Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg, 237, 208-17.
  24. Farinati F, Sergio A, Baldan A, et al (2009). Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. BMC cancer, 9.
  25. Hidaka M, Takatsuki M, Soyama A, et al (2012). Intraoperative portal venous pressure and long-term outcome after curative resection for hepatocellular carcinoma. Br J Surg, 99, 1284-9. https://doi.org/10.1002/bjs.8861
  26. Hollebecque A, Cattan S, Romano O, et al (2011). Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Aliment Pharmacol Ther, 34, 1193-1201. https://doi.org/10.1111/j.1365-2036.2011.04860.x
  27. Ishizawa T, Hasegawa K, Aoki T, et al (2008). Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterol, 134, 1908-16. https://doi.org/10.1053/j.gastro.2008.02.091
  28. Jarnagin WR, Gonen M, Fong Y, et al (2002). Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg, 236, 397-406. https://doi.org/10.1097/00000658-200210000-00001
  29. Jin YJ, Lee JW, Park SW, et al (2013). Survival outcome of patients with spontaneously ruptured hepatocellular carcinoma treated surgically or by transarterial embolization. World J Gastroenterol, 19, 4537-44. https://doi.org/10.3748/wjg.v19.i28.4537
  30. Kawada N, Imanaka K, Kawaguchi T, et al (2009). Hepatocellular carcinoma arising from non-cirrhoticnonalcoholic steatohepatitis. J Gastroenterol, 44, 1190-4. https://doi.org/10.1007/s00535-009-0112-0
  31. Kawano Y, Sasaki A, Kai S, et al (2008). Short- and longterm outcomes after hepatic resection for hepatocellular carcinoma with concomitant esophageal varices in patients with cirrhosis. Ann Surg Oncol, 15, 1670-6. https://doi.org/10.1245/s10434-008-9880-7
  32. Kim JE, Ryoo BY, Ryu MH, et al (2011). Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemother Pharmaco, 68, 1285-90. https://doi.org/10.1007/s00280-011-1616-x
  33. Kubota K, Makuuchi M, Kusaka K, et al (1997). Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatol, 26, 1176-81.
  34. Kulik LM, Chokechanachaisakul A (2015). Evaluation and management of hepatocellular carcinoma. Clin Liver Disease, 19, 23-43. https://doi.org/10.1016/j.cld.2014.09.002
  35. Lammer J, Malagari K, Vogl T, et al (2010). Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol, 33, 41-52. https://doi.org/10.1007/s00270-009-9711-7
  36. Lau WY, Leung TW, Ho SK, et al (1999). Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet, 353, 797-801. https://doi.org/10.1016/S0140-6736(98)06475-7
  37. Lee KK, Kim DG, Moon IS, et al (2010). Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma. J Surg Oncol, 101, 47-53. https://doi.org/10.1002/jso.21415
  38. Lencioni R, Kudo M, Ye SL, et al (2012). First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non- interventional study. Int J Clin Pract, 66, 675-83. https://doi.org/10.1111/j.1742-1241.2012.02940.x
  39. Liang T, Chen EQ, Tang H. (2013). Hepatitis B virus gene mutations and hepatocarcinogenesis. Asia Pac J Cancer Prev, 14, 4509-13 https://doi.org/10.7314/APJCP.2013.14.8.4509
  40. Lin MH, Wu PY, Tsai ST, et al (2004). Hospice palliative care for patients with hepatocellular carcinoma in Taiwan. Palliat Med, 18, 93-9. https://doi.org/10.1191/0269216304pm851oa
  41. Livraghi T, Bolondi L, Lazzaroni S, et al (1992). Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer, 69, 925-9. https://doi.org/10.1002/1097-0142(19920215)69:4<925::AID-CNCR2820690415>3.0.CO;2-G
  42. Livraghi T, Goldberg SN, Lazzaroni S, et al (2000). Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiol, 214, 761-8. https://doi.org/10.1148/radiology.214.3.r00mr02761
  43. Livraghi T, Meloni F (2002). Treatment of hepatocellular carcinoma by percutaneous interventional methods. Hepatogastroenterol, 49, 62-71.
  44. Livraghi T, Meloni F, Di Stasi M, et al (2008). Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatol, 47, 82-9.
  45. Liu L, Chen H, Wang M, et al (2014). Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis. PLoS One, 9, 91124. https://doi.org/10.1371/journal.pone.0091124
  46. Li X, Feng GS, Zheng CS, et al (2004). Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol, 10, 2878-82. https://doi.org/10.3748/wjg.v10.i19.2878
  47. Llop E, Berzigotti A, Reig M, et al (2012). Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. J Hepatol, 56, 103-8. https://doi.org/10.1016/j.jhep.2011.06.027
  48. Llovet JM, Bruix J (2003). Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatol, 37, 429-42. https://doi.org/10.1053/jhep.2003.50047
  49. Llovet JM, Fuster J, Bruix J (1999). Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatol, 30, 1434-40. https://doi.org/10.1002/hep.510300629
  50. Llovet JM, Ricci S, Mazzaferro V, et al (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359, 378-90. https://doi.org/10.1056/NEJMoa0708857
  51. Llovet JM, Schwartz M, Mazzaferro V (2005). Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis, 25, 181-200. https://doi.org/10.1055/s-2005-871198
  52. Lu MD, Chen JW, Xie XY, et al (2001). Hepatocellular carcinoma: US-guided percutaneous microwave coagulation therapy. Radiol, 221, 167-72. https://doi.org/10.1148/radiol.2211001783
  53. Lu MD, Xu HX, Xie XY, et al (2005). Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study. J Gastroenterol, 40, 1054-60. https://doi.org/10.1007/s00535-005-1671-3
  54. Mazzaferro V (2007). Results of liver transplantation: with or without Milan criteria? Liver Transpl, 13, 44-7. https://doi.org/10.1002/lt.21330
  55. Mazzaferro V, Bhoori S, Sposito C, et al (2011). Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl, 17, 44-57. https://doi.org/10.1002/lt.22365
  56. Mazzaferro V, Llovet JM, Miceli R, et al (2009). Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol, 10, 35-43. https://doi.org/10.1016/S1470-2045(08)70284-5
  57. Mazzaferro V, Regalia E, Doci R, et al (1996). Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Eng J Med, 334, 693-9. https://doi.org/10.1056/NEJM199603143341104
  58. Mohamad B, Shah V, Onyshchenko M, et al (2016). Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatol Int, 10, 632-9. https://doi.org/10.1007/s12072-015-9679-0
  59. Nault JC, De Reynies A, Villanueva A, et al (2013). A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterol, 145, 176-87. https://doi.org/10.1053/j.gastro.2013.03.051
  60. Ohmoto K, Yoshioka N, Tomiyama Y, et al (2009). Comparison of therapeutic effects between radiofrequency ablation and percutaneous microwave coagulation therapy for small hepatocellular carcinomas. J Gastroenterol Hepatol, 24, 223-7. https://doi.org/10.1111/j.1440-1746.2008.05596.x
  61. Orlando A, Leandro G, Olivo M, et al (2009). Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol, 104, 514-24. https://doi.org/10.1038/ajg.2008.80
  62. Pai M, Jiao LR, Khorsandi S, et al (2008). Liver resection with bipolar radiofrequency device: Habib 4X. HPB, 10, 256-60. https://doi.org/10.1080/13651820802167136
  63. Poon RT, Fan ST, Lo CM, et al (2004). Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg, 240, 698-708.
  64. Pourhoseingholi MA, Fazeli Z, Zali MR, et al (2010). Burden of hepatocellular carcinoma in Iran; Bayesian projection and trend analysis. Asia Pac J Cancer Prev, 11, 859-62.
  65. Ribero D, Abdalla EK, Madoff DC, et al (2007). Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg, 94, 1386-94. https://doi.org/10.1002/bjs.5836
  66. Roayaie S, Obeidat K, Sposito C, et al (2013). Resection of hepatocellular cancer ${\leq}$2 cm: results from two Western centers. Hepatol, 57, 1426-35. https://doi.org/10.1002/hep.25832
  67. Ruzzenente A, Valdegamberi A, Campagnaro T, et al (2011). Hepatocellular carcinoma in cirrhotic patients with portal hypertension: is liver resection always contraindicated? World J Gastroenterol, 17, 5083-8. https://doi.org/10.3748/wjg.v17.i46.5083
  68. Sacco R, Mismas V, Marceglia S, et al (2015). Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives. World J Gastroenterol, 21, 6518-25. https://doi.org/10.3748/wjg.v21.i21.6518
  69. Salem R, Lewandowski RJ, Kulik L, et al (2011). Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterol, 140, 497-507. https://doi.org/10.1053/j.gastro.2010.10.049
  70. Salem R, Lewandowski RJ, Mulcahy MF, et al (2010). Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of longterm outcomes. Gastroenterol, 138, 52-64. https://doi.org/10.1053/j.gastro.2009.09.006
  71. Somboon K, Siramolpiwat S, Vilaichone RK (2014). Epidemiology and survival of hepatocellular carcinoma in the central region of Thailand. Asian Pac J Cancer Prev, 15, 3567-70. https://doi.org/10.7314/APJCP.2014.15.8.3567
  72. Takayama T, Sekine T, Makuuchi M, et al (2000). Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet, 356, 802-7. https://doi.org/10.1016/S0140-6736(00)02654-4
  73. Toso C, Trotter J, Wei A, et al (2008). Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl, 14, 1107-15. https://doi.org/10.1002/lt.21484
  74. Wanich N, Vilaichone Rk, Chotivitayatarakorn P, et al (2016). High prevalence of hepatocellular carcinoma in patients with chronic hepatitis B infection in Thailand. Asian Pac J Cancer Prev, 17, 2857-60
  75. Wiangnon S, Kamsa-ard S, Suwanrungruang K, et al (2012). Trend in incidence of hepatocellular carcinoma, 1990-2009, KhonKaen, Thailand. Asian Pac J Cancer Prev, 13, 1065-8. https://doi.org/10.7314/APJCP.2012.13.3.1065
  76. Yao FY, Bass NM, Nikolai B, et al (2002). Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl, 8, 873-83. https://doi.org/10.1053/jlts.2002.34923
  77. Yao FY, Kerlan RK Jr, Hirose R, et al (2008). Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatol, 48, 819-27. https://doi.org/10.1002/hep.22412
  78. Yao X, Yan D, Zeng H, et al (2016). Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma. J Surg Oncol, 13, 672-7.
  79. Yin XY, Xie XY, Lu MD, et al (2009). Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors. Cancer, 115, 1914-23. https://doi.org/10.1002/cncr.24196
  80. Yoshida H, Mamada Y, Taniai N, et al (2016). Spontaneous ruptured hepatocellular carcinoma. Hepatol Res, 46, 13-21. https://doi.org/10.1111/hepr.12498
  81. Yoshizumi T, Harimoto N, Itoh S, et al (2016). Living donor liver transplantation for hepatocellular carcinoma within milan criteria in the present era. Anticancer Res, 36, 439-45.
  82. Zhu Q, Li J, Yan JJ, et al (2012). Predictors and clinical outcomes for spontaneous rupture of hepatocellular carcinoma. World J Gastroenterol, 18, 7302-7. https://doi.org/10.3748/wjg.v18.i48.7302
  83. Zhou Y, Zhao Y, Li B, et al (2010). Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol, 10, 78. https://doi.org/10.1186/1471-230X-10-78